PSMA Targeted Strategies and Radioligand Therapies in Prostate Cancer: From Preclinical Models to Clinical Translation

Dear Colleagues,

Prostate-specific membrane antigen (PSMA) has revolutionized the role of both molecular imaging and radiopharmaceutical therapy in the management of prostate cancer. PSMA positron emission tomography’s improved sensitivity and specificity for nodal and distant metastases have allowed for more accurate clinical staging and radiotherapy target volume delineation. PSMA-targeted radiopharmaceuticals have significantly improved survival in patients with metastatic castration-resistant disease, with new prospective data supporting indications in the earlier castration-sensitive setting as well. We expect that these radiopharmaceutical agents will play an increasingly important role in the management of metastatic prostate cancer with the advent of new radioisotopes, including alpha-particle emitters, and new combinations of multimodality therapy. There are many questions left to explore on the optimal integration of radiopharmaceuticals with existing hormone therapies, chemotherapies, and external beam radiotherapy across a variety of clinical settings.

This Special Issue of Cancers, entitled “PSMA Targeted Strategies and Radioligand Therapies in Prostate Cancer: From Preclinical Models to Clinical Translation,” aims to gather original research as well as review papers that examine how PSMA can be leveraged to continue improving the detection, staging, and treatment of prostate cancer. We welcome all contributions to this field.

Prof. Dr. Neha Vapiwala
Dr. John Nikitas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.